Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of May 19, 2026, ZBIO trades at $17.71 with a market cap of $1.16B and a P/E ratio of -1.38. ZBIO moved -7.96% today. Year to date, ZBIO is -50.99%; over the trailing twelve months it is +61.51%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $43.67. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zenas BioPharma Grants 51,075 RSUs to New Hires, Vesting 2027–2030: Zenas BioPharma granted 51,075 restricted stock units to newly hired employees on May 15, 2026 under Nasdaq Listing Rule 5635(c)(4) as inducement awards. The RSUs vest in four equal annual installments on May 15 of each year from 2027 through 2030, subject to continued service under the 2026 Inducement Plan.
| Metric | Value |
|---|---|
| Price | $17.71 |
| Market Cap | $1.16B |
| P/E Ratio | -1.38 |
| EPS | $-11.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.60 |
| 52-Week Low | $5.83 |
| Volume | 1.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.00M |
| Net Income | $-156.99M |
| Gross Margin | 0.00% |
6 analysts cover ZBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $43.67.